microRNA 103b-1 (MIR103B1)

microRNA 103b-1 (MIR103B1) is a small, non-coding RNA that acts as a regulator of gene expression post-transcriptionally via binding complementary sequences in the 3' untranslated region (3' UTR) of target mRNAs, leading to mRNA degradation or translational inhibition[1]. It is part of the miR-103/107 family located on human chromosome 5 and is involved in diverse cellular functions, notably promoting cell proliferation and migration in colorectal and endometrial cancers by targeting tight junction protein ZO-1, among other genes (TIMP3, DAPK, KLF4)[1][4]. MIR103B1 exhibits tissue-specific expression and plays critical roles as an oncogene in several cancers and as a regulator in metabolic and cardiovascular diseases. Its dysregulation is associated with tumorigenesis and metastatic potential. It is considered a novel candidate for miRNA-based therapies and biomarker development in oncology and cardiometabolic disease[1][4][2]. There is some ambiguity in the literature regarding the designation 'MIR103B1' versus 'MIR103-1,' as miR-103 and its variants (miR-103a-1, miR-103b-1) refer to miRNAs encoded at different genomic loci. Database mapping may require clarification to avoid confusion with closely related miRNA genes.

Other names

hsa-mir-103-1-ashsa-mir-103b-1MIR103-1ASMIRN103-1ASmicroRNA 103-1-asmicroRNA 103b-1

Mechanisms for experimental drugs include inhibition of miR-103 activity to restore tumor suppressor gene expression (e.g., targeting ZO-1, TIMP3, DAPK, KLF4 by blocking miR-103 function)[1][4].